Laforest and colleagues conducted the first-in-human 89Zr-trastuzumab PET imaging clinical trial in patients with metastatic BCa [61]: great tumor-to-non tumor contrast was achieved 5+/−1 days post injection in HER2-positive BCa. The gene discussed is ERBB2; the disease is neoplasm.